← Back to patent-cliff list
CAS 96-99-1
4-chloro-3-nitrobenzoic acid
Codes: NINT-012, DABI-011
Application context (from source-drug indications)
Systemic sclerosis-associated interstitial lung diseaseNintedanib EsylateIdiopathic pulmonary fibrosisNintedanib EsylateNon-small cell lung cancerNintedanib EsylatePulmonary fibrosisNintedanib EsylateInterstitial lung diseaseNintedanib EsylateHereditary haemorrhagic telangiectasiaNintedanib EsylateVenous thromboembolismDabigatran Etexilate MesylateEmbolismDabigatran Etexilate MesylateStrokeDabigatran Etexilate MesylateIschaemic strokeDabigatran Etexilate MesylatePulmonary embolismDabigatran Etexilate MesylateVenous thrombosisDabigatran Etexilate Mesylate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Nintedanib Esylate | Tier B — Position early | - |
| Dabigatran Etexilate Mesylate | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
methyl 2-oxo-1,3-dihydroindole-6-carboxylate →(trimethoxymethyl)benzene→N-(4-aminophenyl)-2-(4-methylpiperazin-1-yl)acetamide→1-methylpiperazine→4-chloro-3-nitrobenzoic acid→methyl 4-chloro-3-nitrobenzoate→dimethyl malonate→dimethyl 2-(4-(methoxycarbonyl)-2-nitrophenyl)malonate→2-chloroacetic anhydride→methyl 1-(2-chloroacetyl)-2-oxoindoline-6-carboxylate→(Z)-methyl 1-(2-chloroacetyl)-3-(methoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate→(Z)-methyl 3-(methoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate→ethanesulfonic acid→N-methyl-4-nitroaniline→2-chloroacetyl chloride→2-chloro-N-methyl-N-(4-nitrophenyl)acetamide
4-(methylamino)-3-nitrobenzoic acid→4-(methylamino)-3-nitrobenzoyl chloride→ethyl 3-(pyridin-2-ylamino)propanoate→ethyl 3-(4-(methylamino)-3-nitro-N-(pyridin-2-yl)benzamido)propanoate→ethyl 3-(3-amino-4-(methylamino)-N-(pyridin-2-yl)benzamido)propanoate→2-((4-cyanophenyl)amino)acetic acid→ethyl 3-(2-(((4-cyanophenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate→hexyl carbonochloridate→4-chloro-3-nitrobenzoic acid→4-chlorobenzoic acid→ethyl 3-(2-(((4-(ethoxy(imino)methyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate→ethyl 3-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate oxalate
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | Dabigatran etexilate mesylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | ethyl N-[3-amino-4-(methylamino)benzoyl]-N-pyridin-2-yl-beta-alaninate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | N-(4-cyanophenyl)-Glycine Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-Chloro-N-methyl-N-(4-nitrophenyl)acetamide Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | Trimethyl orthobenzoate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | N-(4-Aminophenyl)-N-methyl-2-(4-methylpiperazin -1-yl)acetamide Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | Methyl 2-oxoindole-6-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | (3E)-2,3-Dihydro-3-(methoxyphenylmethylene) -2-oxo-1H-indole-6- carboxylic acid methyl ester Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.